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Introduction
Hepatitis C virus (HCV) is a hepatotropic RNA virus of the family Flaviviridae that is transmitted parenterally. 1 HCV encodes a single polyprotein that is cleaved by cellular and viral enzymes into the structural proteins core and envelope protein 1 (E1) and E2, the p7 ion channel protein, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B. The capsid protein encases the viral RNA genome and the E1-E2 proteins are embedded into the viral lipid membrane, where they mediate receptor interactions and viral membrane fusion during cell entry. E1 and E2 are also key targets for neutralizing antibodies and thus key structures for vaccine development. Most people exposed to the virus are unable to curtail replication and thus develop a chronic infection. Licensing of direct-acting antivirals (DAAs) has revolutionized HCV patient care, offering a cure for many patients worldwide. 2 However, providing the drugs to more than 140 million chronically infected patients is a major public health challenge. Moreover, treatment-induced cure does not protect from HCV re-infection. Thus, global control of HCV-associated disease burden would benefit from a prophylactic vaccine. However, a vaccine is not available and HCV has developed multiple strategies to evade immune responses; thus vaccine development is a major challenge. Understanding viral immune escape mechanisms is critical for the development of effective vaccination approaches.
HCV replication is linked to host factors and cellular pathways involved in lipid metabolism and remodeling. For instance, apolipoprotein E (ApoE) and ApoCI, both associated with HCV particles, facilitate infection by increasing virus attachment or membrane fusion, respectively. [3] [4] [5] Moreover, circulating lipoproteins like high density lipoprotein (HDL) and oxidized low density lipoproteins (oxLDL) enhance or decrease HCV infection, respectively. [6] [7] [8] Lipoprotein and cholesterol receptors, like Scavenger receptor class B type I (SR-B1), LDL-receptor (LDL-R) and Nieman-Pick-C1-Like 1 (NPC1L1) participate in HCV cell entry. 9 Finally, endogenous expression of ApoB and the exchangeable lipoprotein ApoE are critical for production and release of infectious progeny. 10, 11 In the case of ApoE, direct interactions between NS5A, E1 and E2 have been described and the lack of ApoE expression has been shown to prevent assembly of infectious viral progeny at a stage after envelopment of capsids. [12] [13] [14] [15] Numerous viruses undergo particle maturation on their way through the cellular secretory pathway, concomitant with plasma membrane budding or after virus release. For instance, envelope proteins of several virus families, including retroviruses, orthomyxoviruses and flaviviruses are proteolytically processed by cellular enzymes. In some cases maturation proceeds after release, e.g. proteolytic processing of HIV-1 gag protein by the viral protease. Moreover, for Ebola virus or influenza A virus, proteolytic processing at the surface or within the recipient cell renders virus particles infectious. In the case of HCV, however, little is known about particle maturation processes outside of the virus producing cells, including their impact on cell entry and immune evasion. We aimed to explore if ApoE released from non-infected cells interacts with and modulates secreted HCV particles.
Materials and methods

Production of ApoE enriched supernatant
Huh-7.5 cell ectopically expressing ApoE3 or with an ApoE knockdown by shRNA were created by lentiviral gene transfer. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 2 mM L-glutamine, nonessential amino acids, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% fetal calf serum (PAA Laboratories GmbH) (complete DMEM) and 18 h before supernatant collection, DMEM medium was discarded and serum free OptiMEM was added. The supernatants were passed through a 45 mm filter and subsequently concentrated by using 10 kDa Amicon before ApoE enzyme-linked immunosorbent assay (ELISA) was performed. Recombinant human ApoE2 full length protein (Abcam) was used for immunoprecipitation of Jc1.
Production of HCV
To generate HCVcc, Huh-7.5 cells were electroporated with 5 mg in vitro transcribed RNA as described elsewhere. 16, 17 After electroporation cells were immediately transferred to complete DMEM and seeded in the respective cell culture device. To remove detached cells or cell debris, the supernatant was filtered through a 0.45 mm pore size filter and stored at À80°C.
Quantification of virus infectivity
Standard infection assays with Renilla luciferase reporter viruses were carried out as described elsewhere. 10 
ELISA
HCV core protein containing samples were inactivated with Triton X-100 (Roth) at a final concentration of 1% (v/v) and HCV core protein was quantified with a diagnostic kit (Architect Anti-HCV; Abbott). Extracellular apolipoproteins (ApoE, ApoB and ApoCI) were measured by using the human ApoE ELISA kit (Cell Biolabs, USA), the human ApoB ELISA kit (Cell Biolabs, USA) and the human ApoCI ELISA kit (Cell Biolabs, USA). The ITX5061 inhibitor was a kind gift from F. Wong-Staal. Heparin sodium salt from bovine lung (Calbiochem, Darmstadt, Germany) and heparan sulfate sodium salt from bovine kidney (Sigma-Aldrich, Munich, Germany) were used in infection assays.
Iodixanol density gradient fractionation
Density gradient centrifugation was performed as described recently. 33 Briefly, viruses were separated by an overnight centrifugation through a 0-40% iodixanol step gradient at 154,000 x g in a TH-641 swing-out rotor at 4°C using a Sorvall Ultra WX80 centrifuge. Ten to eleven fractions of 1 ml were collected from the bottom and analysed for virus infectivity.
Monoclonal antibody and inhibitor-mediated blocking of HCV infection
For inhibition of HCV infection, 200 ml of a Huh-7.5 cell suspension (5 Â 10 4 cells per ml) was seeded into each well of a 96-well plate 24 h prior to inoculation. Luciferase reporter viruses were mixed with serial dilutions of E1 or E2-specific antibodies as indicated in the text and were used to inoculate cells.
Precipitation of HCV particles with antibodies
Equal quantities of HCV particles were subjected to immunoprecipitation with 1 mg anti-E2 antibodies or an isotype-matched control antibody R04 (anti-CMV). Antibodies and HCV RNA-containing particles recognized by the antibodies were incubated for 2 h at 4°C and were then precipitated by the addition of 25 ll protein G agarose. The agarose beads were incubated with the samples overnight at 4°C with rotation. Immunoprecipitated material was washed 3 times with PBS. Finally, precipitated viral RNA was quantified using qRT-PCR as described above.
Primary human hepatocytes and HCV patient sera
Primary human hepatocytes (PHH) were obtained from the department of General, Visceral, and Transplant Surgery at Hannover Medical School (Hannover, Germany) and cultured as described elsewhere. 18, 19 HCV patient sera were collected at the department of Gastroenterology, Hepatology and Endocrinology with informed written consent. Use of HCV sera and primary hepatocytes was approved by the local Ethics committee.
Production of CRISPR-Cas9 knockout cell line
Single guide RNA (sgRNA) sequences targeting SR-BI were selected using CHOPCHOP. 20 Lentiviral plasmids containing one sgRNA were then generated as described previously. 21, 22 LentiCRISPRv2 containing the SR-BI sgRNA sequence was co-transfected with the packaging plasmids pVSV-G and pcMV_DR8-74 into 293T cells using a Lipofectamin 2000 method according to the manufacture's instruction. Virus was harvested two days post transfection, filtered through 0.45 mm pore size filters and used to transduce Lunet N#3-hCD81 cells. Three days post transduction, Puromycin selection pressure was applied and cells were cultured in selection medium for five passages. Afterwards, single cell clones were generated to produce cells with complete SR-BI knockout. To this end, Lunet N#3-hCD81-CRISPR sg SR-BI were seeded at a density of 0.5 cells per well into two 96 well plates. Cells were incubated until colonies started to grow and SR-BI knockout cell line was confirmed by Western blot.
Statistics
Data were analysed using GraphPad Prism V.6.0b (GraphPad Software, La Jolla, California, USA For further details regarding the materials used, specifically antibodies used, please refer to the CTAT table.
Results
Physiological quantities of extracellular ApoE increase infectivity of HCV from hepatoma cell lines and primary human hepatocytes
We examined if HCV particles undergo ApoE-dependent maturation after secretion. Since the concentration of ApoE in Huh-7.5 cell-derived culture supernatants is $100-fold lower compared to ApoE serum levels ($10-60 mg/ml; Fig. 4C ) we first established experimental conditions comparable to those in vivo. We modulated ApoE expression in Huh-7.5 cells by either overexpression or shRNA-mediated silencing, and used concentrated culture fluids of these cells as a source of secreted ApoE. Serial dilutions of concentrated culture fluids were incubated with HCV before inoculation of target cells (Fig. 1A and B) . Indeed, incubation of HCV particles with culture fluids of ApoE-overexpressing cells reproducibly and dose-dependently increased HCV infectivity by up to 8-fold (Fig. 1A) . In contrast, incubation of these particles with equal dilutions of control supernatant from ApoE-silenced cells did not modulate HCV infectivity (Fig. 1A) . Plotting the same results, according to the amount of ApoE present in the culture fluid incubated with HCV, revealed that HCV infectivity was increased once the culture fluid contained ApoE levels greater than 5 mg/ml (Fig. 1B) . Extracellular ApoC1 enhances HCV membrane fusion in a process that requires the hypervariable region one (HVR1) at the Nterminus of the HCV E2 protein. 4 To explore if HCV infection enhancement by secreted ApoE requires HVR1, we deleted this protein domain. However, boosting of HCV/DHVR1 particle infectivity was readily detectable, occurred in a dose-dependent manner and was even greater compared to parental particles ( Fig. 1C and D) . Thus, physiological levels of secreted ApoE, in contrast to ApoC1, stimulate HCV infection independently of HVR1.
To confirm that ApoE, and no other factors secreted from ApoE expressing cells, enhance HCV infectivity, we selectively depleted ApoE by subjecting culture fluids to four consecutive rounds of immuno-precipitations with ApoE-specific antibodies, prior to co-culture with HCV particles (Fig. 2 ). This procedure reduced HCV infection enhancement and ApoE levels, but not ApoB or ApoC1 quantities, in a step-wise manner (Fig. 2) . Thus, selective depletion of ApoE, but no other lipoproteins, ablated the infection-enhancing effect.
Next, we determined if the infectivity of chimeric HCV representing all HCV genotypes is stimulated by secreted ApoE as well, and if infectivity of HCV from PHH is enhanced by physiological levels of secreted ApoE ( Fig. 3A and B ). We detected a mean stimulation of HCV infectivity of 3-to 8-fold across all viral strains and in four independent experiments (Fig. 3A) . Moreover, infectivity of PHH-derived genotype 2a (Jc1) and genotype 5a virus particles and also of the HCV/DHVR1 variant was increased ca. 5-fold (Fig. 3B) . Therefore, infectivity of HCV particles across all known genotypes and irrespective of particle source (cell line or PHH), is enhanced by secreted ApoE. HCV particles interact with lipoproteins and display highly variably buoyant density. To investigate if particle density determines whether secreted ApoE modulates particle infectivity, we resolved Jc1, Jc1/DHVR1 or SA13 genotype 5a viruses according to their buoyant density by gradient centrifugation. Viruses contained in separate fractions were incubated with equal quantities of secreted ApoE containing culture fluid or control culture fluid collected from ApoEsilenced Huh-7.5 cells ( Fig. 3C and D) . For all three viruses infectivity was enhanced between 2-to 10-fold across all fractions of the density gradient ( Fig. 3C and D) . Taken together these results indicate that secreted ApoE enhances infectivity of secreted HCV particles across all genotypes and irrespective of whether these particles are produced in hepatoma cells or PHH.
Secreted ApoE incorporates into secreted HCV particles
HCV infection enhancement may occur indirectly, i.e. by modulation of host cells or by direct incorporation into HCV particles. To distinguish between these two possibilities, we rescued ApoE expression in the Huh-7.5/ApoE-shRNA cell line by ectopic expression of a shRNA-resistant ApoE variant with an HA-epitope tag. Since the culture fluid of these cells contains primarily secreted HA-ApoE, it was used as bait for HA-specific affinity purification of HCV particles incubated with these supernatants. Co-precipitation of HCV particles was evaluated by detection of core protein. HCV particles incubated with culture fluid collected from ApoE overexpressing Huh-7.5 cells served as control and resulted in co-precipitation of background levels of HCV core protein (ca. 500 fmol/L) (Fig. 4A) . In contrast, incubation of HCV particles (Jc1, Jc1/DHVR1 or genotype 5a virus) with HA-ApoE containing culture fluid resulted in co-precipitation of ca. 30,000 fmol/L core protein corresponding to a ca. 60-fold increase (Fig. 4A) , indicating that secreted HA-ApoE interacts with HCV particles secreted from Huh-7.5 cells. To obtain evidence that secreted untagged ApoE can also be incorporated into HCV particles, we used HCV particles secreted from Huh-7.5 and from Huh-7.5/ApoE-shRNA cells and incubated them with secreted ApoE. Interaction of ApoE with these particles was quantified by co-precipitation of viral RNA after affinity purification with ApoE-specific antibodies. Addition of secreted ApoE at a dose of 0.5 mg/ml significantly enhanced co-precipitation of viral RNA of HCV particles from Huh-7.5/ApoE-shRNA cells, but not from Huh-7.5 cells (Fig. 4B ). This indicates that secreted untagged ApoE is capable of being incorporated into secreted HCV particles, and that the ability to do so may (at least in part) be determined by endogenous levels of ApoE.
To explore if HCV particles circulating in human blood accept secreted ApoE, we incubated HCV particles in sera of HCVinfected donors containing varying levels of serum ApoE with HA-ApoE secreted from Huh-7.5/ApoE-shRNA/HA-ApoE cells and subjected them to affinity purification with anti-HAantibodies (Fig. 4C) . In several patient samples, incubation of HCV particles with HA-ApoE increased co-precipitation relative to incubation of particles with parental ApoE. Co-precipitation, and thus interaction with HA-ApoE, was less efficacious compared to Huh-7.5-derived particles. There was a trend that showed the interaction of HCV from sera with HA-ApoE was greater when serum ApoE levels were lower (Fig. 4D) , suggesting that high serum levels of ApoE may have saturated binding sites on virus particles. Moreover, HCV particles circulating in human blood are much more likely to be heavily decorated with ApoE, as shown by greatly increased recruitment of ApoE to anti-E2 antibody-coated ELISA plates when compared to Jc1 particles produced in Huh-7.5 cells (Fig. 4E) . These results indicate that secreted ApoE was incorporated into secreted particles from tissue culture and from patients. Moreover, endogenous cellular ApoE levels may influence the capability of secreted particles to accept secreted ApoE. Notably, HCV particles circulating in vivo are associated with more ApoE compared to cell culturederived viruses.
Infection enhancement by secreted ApoE is ablated by heparin and heparinases
To characterize the mode of infection enhancement by secreted ApoE, we performed a time-of-addition assay with Jc1, Jc1/ DHVR1 and SA13 viruses (Fig. 5 ). Cells were either treated with secreted ApoE for 4 h prior to inoculation (white bar), during inoculation (light blue bar) or for 4 h after inoculation (dark blue bar). Exogenous ApoE was proviral only when present during virus inoculation, indicating enhancement of cell entry.
ApoE has been shown to be part of the HCV infectious virion 23, 24 facilitating virus attachment through interactions with heparin sulfate proteoglycans (HSPGs). 5 Moreover, ApoC1-mediated infection enhancement was shown to be mediated by HVR1 and SR-BI. 4 Therefore, we examined HSPG-and SR-BIdependence of HCV infection enhancement by secreted ApoE. 
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ApoB of input ApoE depletion I n p u t A f t e r 1 . I P A f t e r 2 . I P A f t e r 3 . I P A f t e r 4 . I P When blocking SR-BI using either the SR-BI-specific inhibitor ITX5061 or the monoclonal anti-SR-BI antibody C167, we found no effect on extracellular ApoE-mediated infection enhancement suggesting an SR-BI independent mechanism (Fig. 6A ). This was corroborated in Huh-7.5 cells with SR-BI knockout. In the absence of SR-BI secreted ApoE-mediated infection enhancement was still observed (Fig. 6B) . Next, we used heparin, a highly sulphated soluble glucosaminoglucan and effective competitor of HSPG-dependent interactions, to counteract the infection enhancement afforded by secreted ApoE. Addition of heparin, concomitant with secreted ApoE, inhibited the proviral effect of secreted ApoE dosedependently (Fig. 6C) . Moreover, pretreatment of Huh-7.5 cells with heparinase III, an enzyme that cleaves cell surface resident heparan sulfate moieties, abrogated ApoE infection enhancement (Fig. 6C) .
HCV infection enhancement by physiological levels of secreted ApoE results in increased virus resistance to neutralizing antibodies
To determine the impact of physiological levels of ApoE on neutralization of HCV by antibodies, we selected a panel of E1-and E2-targeting monoclonal antibodies covering a broad range of different conserved neutralizing epitopes and conducted neutralization assays, in the presence or absence of secreted ApoE (Fig. 7A) . Addition of secreted ApoE attenuated the antiviral activity of all tested monoclonal antibodies, as evidenced by a 2-to 10-fold increase of the IC 50 irrespective of the epitope that was targeted (Fig. 7A) . Desensitization of antibody potency was generally greatest for the Jc1/DHVR1 variant whose infectivity is most effectively stimulated by secreted ApoE, suggesting that the degree of ApoE-dependent enhancement modulates efficacy of viral antibody escape.
To examine if secreted ApoE occludes antibody binding sites on virus particles, we immuno-captured HCV using distinct E2-targeting antibodies in the presence or absence of secreted ApoE (Fig. 7B) . Efficiency of HCV capture was determined by the detection of co-precipitated viral core, which was, however, not affected by ApoE. In conclusion, physiological levels of ApoE reduced the potency of neutralizing antibodies targeting varying conserved epitopes in HCV E1 and E2, without inhibiting antibody binding.
Discussion
Numerous viruses undergo particle remodeling and maturation after release from host cells. Therefore, we explored if HCV particles also mature after release from infected cells.
The results summarized here indicate that physiological levels of ApoE, secreted from human liver cell lines, enhance HCV particle infectivity across all known HCV genotypes. Moreover, we provide evidence that infection enhancement occurs through direct interaction of HCV particles with secreted ApoE, since secreted HA-ApoE or secreted ApoE were able to incorporate into virus particles after their release from cells, as shown by a series of co-immunoprecipitation experiments (Fig. 4) . Secreted ApoE was also incorporated into patient serum-derived HCV particles, albeit to a lower extent. This could be due to serum-derived HCV particles being suspended in an environment with much higher ApoE concentrations (serum ApoE levels 10-60 mg/ml) compared to cell culture-derived HCV, present in culture supernatants containing ApoE concentrations of around 0.3 mg/ml. In addition, serum-derived HCV particles carry higher levels of ApoE compared to Huh-7.5-derived viruses, which is supported by the experiment showing that anti-E2-coated ELISA plates captured much greater quantities of ApoE when incubated with serumderived HCV instead of Huh-7.5 derived Jc1 particles (Fig. 4E ). Both the high serum level of ApoE and the more extensive association of ApoE with serum-derived particles may competitively inhibit access of exogenously added HA-ApoE to serum-derived particles. In fact, we believe that the high ApoE serum levels are at least partially responsible for ApoE saturation of serumderived HCV particles. The indirect correlation between ApoE serum levels and the ability of serum-derived HCV particles to interact and thus co-precipitate with exogenously added HA-ApoE supports this conclusion. The reason for the different loading of cell culture-derived and serum-derived particles with ApoE remains elusive. At least two scenarios, which are not mutually exclusive, can be envisioned.
Firstly, Huh-7.5 cells are known to express a somewhat rudimentary cellular machinery for lipoprotein synthesis and secretion. 25 This may lead to incomplete loading of ApoE onto virions during intracellular assembly compared to virus production in authentic PHH. Alternatively, or in addition, a much lower abundance of secreted ApoE in the culture fluid of Huh-7.5 cells than ApoE blood levels may lead to incomplete ApoE incorporation after particle secretion or loss of virus-associated ApoE. Currently, we cannot distinguish between these scenarios. However, we also show that the infectivity of HCV particles from PHH is enhanced by exogenous addition of secreted ApoE (Fig. 3) . Thus, in this most authentic cell culture model, intracellular assembly does not saturate HCV particles with ApoE, supporting the notion that in vivo terminal maturation and saturation with ApoE may occur only extracellularly in the blood stream. Moreover, we provide evidence that intracellular abundance of ApoE can modulate the efficacy of extracellular incorporation of secreted ApoE, because silencing of endogenous cellular ApoE facilitated the incorporation of secreted ApoE (Fig. 4) . Thus, it is possible that both in cell culture and in vivo ApoE is incorporated into HCV in a dynamic manner that is initiated during -and important for -intracellular assembly, which continues after virus release in the blood stream to complete virion maturation. ApoE is an exchangeable apolipoprotein that readily alters conformations depending on lipid availability and that can exchange between lipoproteins. It is thus conceivable that HCV particles are To analyse the degree of ApoE decoration, Jc1 or sera from HCV-infected patients and serum from a healthy donor were captured by E2-specific antibodies (AR4A, CBH5, HC11) and captured core and ApoE was eluted with 50 ml PBS/1% Triton and quantified using ApoE ELISA and core ELISA. One representative experiment is shown (n = 3). dynamically remodeled post release by circulating ApoE. This notion is also supported by our finding that patient derived HCV particles carry highly divergent levels of ApoE (Fig. 4E) , which may be a consequence of such remodeling events.
While this manuscript was in preparation, Yang and colleagues also reported on the supportive role of exogenous ApoE on virus infectivity by using an alternative approach. 26 Our results confirm and further extend this previous report by: i) showing that primary hepatocyte-derived HCV particles are also remodeled by ApoE, ii) by highlighting the dramatic impact of extracellular particle maturation on antibody-dependent neutralization, iii) by showing that patient derived HCV can accept ApoE, and finally iv) by reporting patient-specific differences regarding the amount of ApoE associating with virus particles. Lindenbach et al. reported a much greater infectivity of HCV particles produced in an animal model (humanized mice repopulated with PHH), compared to cell culture-derived HCV particles. 27 Since particles from animals displayed lower buoyant density and as this feature and the high infectivity were lost after a single passage in cell culture, they postulated that the incorporation of host factors -possibly lipoproteins -during in vivo passage of the virus was responsible for this. It is tempting to speculate that the divergent amount of ApoE present in the animal-derived viruses, compared to the ones obtained in cell culture, may be responsible for this. It is unclear which viral determinants mediate incorporation of ApoE and which domains of ApoE are critical to engage with HCV particles after virus secretion. In principle it is possible that protein-protein and/or protein-lipid interactions mediate this interplay. Previous reports highlighting interactions between ApoE and E1 and E2 within infected cells 13 suggest that these viral proteins, which are major constituents of virions, may be involved. Since we were able to show that viruses lacking the HVR1 at the N-terminus of E2 still incorporate secreted ApoE and are strongly stimulated in infection, we can rule out that this protein domain is critical for the recruitment of extracellular ApoE. At the same time this result distinguishes infectivity modulation by secreted ApoE from the previously described infection Renilla luciferase reporter viruses (JcR2a, JcR2a/DHVR1 and SA13/5a/R2a) were incubated with ApoE enriched supernatant (20 mg/ml ApoE) or control supernatant ($0.2 mg/ml ApoE) for 20 min at 37°C. Subsequently, viruses were incubated for 1 h at 37°C with serial dilutions of antibodies specific for E1 (IGH526) or E2 (CBH7, HC11, AP33, AR4A) prior to infection of Huh-7.5 cells. 72 h after infection luciferase assay was performed. Mean values of three independent experiments including the standard deviations are shown. (B) Equal numbers of given viruses were incubated with ApoE enriched supernatant (20 mg/ml ApoE) or control supernatant ($0.2 mg/ml ApoE) for 20 min at 37°C. Subsequently, viruses were incubated with 1 mg of the specified antibodies. Immune complexes were precipitated using protein A/G-coated beads, and associated HCV core protein was quantified by ELISA. Mean values of at least two independent experiments including the standard deviations are shown. enhancement effect of ApoC1, which depends on HVR1. 4 Moreover, we observed that SR-B1 is dispensable for ApoE-mediated enhancement of HCV infection, which is also different from ApoC1-dependent HCV fusion enhancement shown to depend on this factor. 4 Several studies have highlighted that ApoE incorporated into HCV particles is mediating the binding of HCV particles to cell surface proteoglycans. 5, 28, 29 Our data showing that heparinase treatment of target cells and the addition of heparin, a competitive inhibitor of HSPG interactions, ablate the infection enhancement by secreted ApoE support the conclusion that maturation of HCV particles, by the incorporation of extracellular ApoE, enhances HCV infectivity through the improvement of particle-HSPG interactions. Antibody-mediated neutralization of HCV was shown to be attenuated by serum components like HDL in a process that depends on SR-BI and HVR1. 6, 7, 30, 31 Here, we unravel a new role of secreted ApoE for viral escape that was independent of SR-BI and HVR1. For a broad panel of E1-and E2-specific monoclonal antibodies targeting different conserved neutralizing epitopes we observed 2-to 10-fold higher IC 50 values when secreted ApoE was added at levels comparable to physiological serum levels. This indicates that the incorporation of ApoE into secreted viruses globally reduces virus neutralization by antibodies. This observation is in line with a previous report 32 demonstrating that virus particles produced in hepatoma cells, expressing only low levels of ApoE, are more sensitive to antibody-mediated neutralization. We observed that not only intracellular, but also extracellular, ApoE concentrations have implications for antibody-dependent neutralization. Together, these studies strongly support the conclusion that the amount of particle-associated ApoE profoundly modulates virus neutralization. Since we show that addition of secreted ApoE did not reduce antibody binding to virus particles in solution, decreased neutralization is likely due to the ApoEdependent increase in the interaction between virus particles with the hepatocyte cell surfaces, through HSPGs which mediate infection enhancement. These observations have several important implications: firstly, evaluation of neutralizing antibody responses in cell culture assays, including comparison of these data between laboratories, should take into account the amount of ApoE present in the assays and within the virus preparation. Given the strong influence of secreted ApoE on virus neutralization it will be critical to develop and use standardized protocols to compare findings between different laboratories. Secondly, modulation of the interaction of secreted ApoE with circulating particles might be a useful strategy to impede HCV infection and antibody evasion with possible therapeutic merits. Finally, the detailed understanding of how HCV usurps circulating lipoproteins for immune evasion and cell entry may guide the pathway towards a prophylactic HCV vaccine that could complement DAAs to reduce the global health burden of hepatitis C.
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